News for Royalty Pharma plc (RPRX)

PR NewswireNEW YORK, June 2, 2025 NEW YORK, June 2, 2025 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeli

PR NewswireDUBLIN, June 2, 2025 Definitive agreement to result in one-time $225 million cash payment Theravance Biopharma retains rights to up to $150 mill

Morgan Stanley has resumed its coverage of Royalty Pharma (RPRX), assigning it an Overweight rating and setting a price target of $51. The financial institution

PR NewswireDUBLIN, May 8, 2025 YUPELRI® (revefenacin) net sales of $58.3 million, recognized by Viatris, increased 6% versus Q1 20241 TRELEGY net sales of

**media[618818]**

PR NewswireCAMBRIDGE, Mass., May 1, 2025 -- Achieved 61% year-over-year growth with $149.4 million in AYVAKIT net product revenues in the first quarter 202

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (”œPureTech” or the ”œCompany”) today announces its results for the year ended December 31, 2024, as well a

Royalty Pharma PLC (RPRX) has announced its participation in a fireside chat at TD Cowen's 45th Annual Health Care Conference, scheduled for March 4, 2025, at 2

**media[552855]**

**media[552844]**

PR NewswireDUBLIN, Feb. 26, 2025 YUPELRI® (revefenacin) US net sales, recognized by Viatris, reached an all-time high of $66.7 million in Q4 2024 and $238

Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today reported fi

We recently published a list of the 10 Best Performing Pharma Stocks So Far in 2025.

On February 20, Jared Holz, Mizuho healthcare sector strategist, appeared on 'Squawk Box' to discuss the potential challenges and opportunities the pharmaceutical industry may face under the new Trump...

Robust market share with approximately 51% of all royalty transactions from 2020 through 2024.Portfolio includes royalties on 15 therapies with end-market sale

Royalty Pharma's Q4 results show portfolio receipts of $742 million and operating cash flow of $678 million. Read why RPRX stock is a Buy.

On December 31, 2024, FMR LLC (Trades, Portfolio), a prominent investment firm, made a strategic decision to reduce its holdings in Royalty Pharma PLC (RPRX) by

Operator: Ladies and gentlemen, thank you for standing by, and welcome to the Royalty Pharma Fourth Quarter Earnings Conference.

Royalty Pharma partners with Biogen, investing $250M in groundbreaking Phase 3 drug litifilimab for lupus.